Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor

Cocrystal Pharma, Inc.

CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
No serious adverse events, severe TEAEs, or clinically significant lab/ECG findings; all 48 participants completed.
CDI-988 targets a conserved 3CL protease region; potential first dual broad-spectrum treatment for norovirus and coronavirus.
MAD cohort enrollment planned to start in Q4 2024; drug product currently being manufactured.
Norovirus causes ~21M US cases/year; no approved antiviral or vaccine for norovirus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.